Kinevant

Kinevant Sciences is a clinical-stage biopharmaceutical company that develops novel therapies for rare autoimmune and inflammatory diseases. The company adopts a patient-first approach in drug development, offering candidates the potential to address underlying diseases and create life-changing benefits for patients. Kinevant is initially focused on treating sarcoidosis with namilumab, an anti-GM-CSF monoclonal antibody, which is currently being evaluated in patients with pulmonary sarcoidosis in the Phase 2 RESOLVE Lung study.